Allied Journal of Medical Research

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Review Article - Allied Journal of Medical Research (2017) Volume 1, Issue 1

The impact of Renin-angiotensin system blockers on lung cancers prognosis: A prisma-compliant systematic review and meta-analysis.

Background and objective: The impact of antihypertensive medications angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) on the clinical outcomes of lung cancer patients remains controversial. This meta-analysis was conducted to investigate the association between ACEIs/ARBs usage and survival of lung cancer patients.

Methods: Eligible studies were identified by searching Pubmed, Embase and Cochrane library up to February, 2017. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated for the effect of ACEIs/ARBs on survival of lung cancer. Heterogeneity and sensitivity were also analyzed.

Results: We finally included 9 eligible studies (8 articles) with the total number of 29,156 patients in this meta-analysis. Our results showed that ACEIs/ARBs usage was associated with favorable overall survival (OS) (HR, 0.86; 95% CI, 0.76–0.98) in lung cancer patients. Moreover, the significant association was found in subgroup of advanced clinical stage (IIIb to IV) (HR, 0.77; 95% CI, 0.64-0.92) and non-small cell lung carcinoma (NSCLC) (HR, 0.78; 95% CI, 0.65–0.93). However, no significant association was revealed between ACEIs/ARBs usage and progression-free survival (PFS) (HR, 0.84; 95% CI, 0.70–1.02).

Conclusions: ACEIs/ARBs statistically significantly prolong OS of lung cancer patients, especially in advanced clinical stage or patients with NSCLC. However, it has no demonstrable impact on PFS.

Author(s): Ning Wang, Jia Liu, Wenting Wang, Jinguang Qin, Dianjie Lin

Abstract Full Text PDF